Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs.

UNLABELLED The use of radiolabeled thymidine (TdR) and thymidine analogs as PET-based tracers of tumor growth rate is based on the assumption that measurement of uptake of these nucleosides, a function primarily of thymidine kinase-1 (TK(1)) activity, provides an accurate measure of active cell proliferation in tumors. The goal of this study was to test this hypothesis and determine how well these tracers track changes in proliferation of tumor cells. METHODS TK(1) activity; S-phase fraction; and uptake of TdR, 3'-deoxy-3'-fluorothymidine (FLT), and 2'-fluoro-5-methyl-1-(beta-D-2-arabino-furanosyl) uracil (FMAU) were determined in plateau-phase and exponentially growing cultures of 3 human and 3 murine tumor cell lines. RESULTS TK(1) activity and S-phase fraction increased in all cell lines as cells moved from plateau-phase conditions to exponential growth. Some cell lines had relatively large TK(1) activities and S-phase fractions under plateau-phase conditions, consistent with a loss of normal cell cycle checkpoint control in these cells. There were also 2 cell lines in which TK(1) activity changed little as cells moved from the plateau phase to exponential growth, suggesting that in these cell lines, de novo nucleotide synthesis pathways predominate over salvage pathways. Both TdR and FLT detected changes in TK(1) activity. The slope of the relationship between TdR uptake and TK(1) activity was nearly twice that for FLT and more than 40-fold that for FMAU. CONCLUSION Although not all tumors show a strong TK(1) dependence of proliferation, in all cell lines for which proliferation is highly TK(1) dependent, phosphorylation of TdR or FLT accurately reflects changes in TK(1) enzyme activity.

[1]  B. Kamen,et al.  Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs , 2002, Cancer Chemotherapy and Pharmacology.

[2]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Y. Yonekura,et al.  Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.

[4]  K Kubota,et al.  From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology , 2001, Annals of nuclear medicine.

[5]  D. Mankoff,et al.  Imaging Cellular Proliferation as a Measure of Response to Therapy , 2001, Journal of clinical pharmacology.

[6]  I. van der Tweel,et al.  Proliferative capacity in head and neck cancer , 2001, Head & neck.

[7]  D. Mankoff,et al.  Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. , 2001, Seminars in radiation oncology.

[8]  A. Padhani,et al.  FDG–PET in the prediction of survival of patients with cancer of the pancreas: a pilot study , 2000, British Journal of Cancer.

[9]  J. Bading,et al.  Pharmacokinetics of the thymidine analog 2'-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells. , 2000, Nuclear medicine and biology.

[10]  R. Blasberg,et al.  Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. , 2000, Cancer research.

[11]  M. Graham,et al.  Determining Hypoxic Fraction in a Rat Glioma by Uptake of Radiolabeled Fluoromisonidazole , 2000, Radiation research.

[12]  D. Mankoff,et al.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. , 2000, Neoplasia.

[13]  F. Apiou,et al.  Purine metabolism in two human melanoma cell lines: relation to proliferation and differentiation. , 1999, Melanoma research.

[14]  Norbert Avril,et al.  Relevance of Positron Emission Tomography (PET) in Oncology , 1999, Strahlentherapie und Onkologie.

[15]  D. Mankoff,et al.  Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M. Berger,et al.  2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.

[17]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[18]  N. Weidner,et al.  Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. , 1998, Lung cancer.

[19]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[20]  A. Shields,et al.  Development of labeled thymidine analogs for imaging tumor proliferation. , 1996, Nuclear medicine and biology.

[21]  R L Wahl,et al.  Squamous Cell Carcinoma of the Head and Neck , 2006 .

[22]  B. Dutrillaux,et al.  Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. , 1994, British Journal of Cancer.

[23]  E. Wintersberger,et al.  Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. , 1994, The Journal of biological chemistry.

[24]  S. Leskinen-Kallio Positron emission tomography in oncology. , 1994, Clinical physiology.

[25]  A. Begg Prediction of repopulation rates and radiosensitivity in human tumours. , 1994, International journal of radiation biology.

[26]  V. McKelvey-Martin,et al.  Thymidine kinases: the enzymes and their clinical usefulness. , 1993, Cancer biotherapy.

[27]  L. Dressler DNA flow cytometry measurements as surrogate endpoints in chemoprevention trials: Clinical, biological, and quality control considerations , 1993, Journal of cellular biochemistry. Supplement.

[28]  E. Wintersberger,et al.  Regulation of thymidine kinase during growth, cell cycle and differentiation. , 1992, Advances in enzyme regulation.

[29]  M. Prados,et al.  Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. , 1989, Journal of neurosurgery.

[30]  P. Keng,et al.  Growth phase related variation in the radiation sensitivity of human colon adenocarcinoma cells. , 1988, International journal of radiation oncology, biology, physics.

[31]  I. Tannock,et al.  Cell kinetics and chemotherapy: a critical review. , 1978, Cancer treatment reports.

[32]  J. Rasey,et al.  Cure of EMT-6 tumors by X rays or neutrons: effect of mixed-fractionation schemes. , 1977, Radiology.

[33]  E. Hall,et al.  Radiobiology for the radiologist , 1973 .